Unfortunately there are so many other cash payments
of course, I am aware of this. Nevertheless, I find it astonishing that the two positions mentioned have remained almost unchanged in total.
However, the comparison with Q4/2020 seems more important to me, given that the zinc price on average was lower and the treatment charges significantly higher then. Therefore I would have expected a higher EBITDA now. it is also noticeable that the recovery rate was not mentioned.
NCZ Price at posting:
22.0¢ Sentiment: None Disclosure: Not Held
